Loading clinical trials...
Loading clinical trials...
An 8-week, Randomised, Double Blind, Parallel-group, Multi-centre, Phase III Study Comparing the Efficacy and Safety of Symbicort® Turbuhaler® 160/4.5 µg Twice Daily and Pulmicort® Turbuhaler® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Patients With Asthma
Conditions
Interventions
Budesonide/Formoterol
Budesonide
+1 more
Locations
43
Japan
Research Site
Komaki, Aichi-ken, Japan
Research Site
Seto, Aichi-ken, Japan
Research Site
Asahi, Chiba, Japan
Research Site
Noda, Chiba, Japan
Research Site
Touon, Ehime, Japan
Research Site
Miyaodai, Fukuoka, Japan
Start Date
October 1, 2005
Completion Date
November 1, 2006
Last Updated
January 24, 2011
NCT02327897
NCT07219173
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions